Kevin Slawin, M.D. is the Founder and CEO of Perseus SENOLYTIX, a cancer-focused company, which together with sister entity Eos SENOLYTIX, a longevity company, are developing lead programs powered by their proprietary MitoXcel™ Technology, targeting aging mitochondria to improve healthspan and potentially increase lifespan via two novel mechanisms. Together with Damian Young, Ph.D. and David M. Spencer, Ph.D., he is the co-Founder and CEO of Deliver Therapeutics, Inc., applying high throughput DNA encoded library (DEL) drug screening in novel ways to “deliver” small molecule therapeutics that are both best-in-class and first-in-class, addressing some of the most difficult clinical challenges in cancer medicine.
He is also the Founder and CEO of Phoenix SENOLYTIX, a longevity company developing novel gene therapies targeting senescent cells, among other fundamental mechanisms of aging. He was the co-founder of Bellicum Pharmaceuticals, Inc., the first CAR T cell company, leading Bellicum to a successful $161 million IPO in December, 2014. He is also Founder, Chairman and CEO of PrintBio, Inc., the only clinical- and commercial-stage regenerative medicine company that has implanted 3D-bioprinted living implants in patients. He currently lives in Miami, FL where he is Founder and CEO of Miami Medicos, a membership organization of physicians, founders, executives, and investors catalyzing the healthcare entrepreneurial ecosystem in Miami and worldwide.
